If at some point Congress or the administration does pursue further intellectual property enforcement in legislation, trade agreements or other policy, the key first step should be a clear assessment of the scope and nature of the problem so that the policy is appropriate and makes sense.
The FDA studies on the pharmacokinetics of BPA have gone where no assessment of an environmental chemical has ever gone before in terms of scope and sophistication.